John Harris

Company: Alys Pharmaceutical

Job title: Chief Innovation Officer

Seminars:

Targeting Durable Repigmentation through Tissue‑Resident Immune Control in Vitiligo 11:20 am

Resident memory CD8⁺ T cells persist in vitiligo lesions and drive relapse even after repigmentation with JAK inhibitors IFN‑γ signaling via JAK pathways mediates depigmentation yet inhibition does not deplete Trm cells, limiting treatment durability Blocking IL‑15 signaling shows promise in mouse models to eliminate Trm and achieve sustained repigmentation beyond temporary response Emerging clinical…Read more

day: Day One AM